The Bull Case For Regeneron (REGN) Could Change Following New Dupixent BP Approval In Japan - Learn Why

• Regeneron Pharmaceuticals and Sanofi recently received approval from Japan’s Ministry of Health, Labour and Welfare for Dupixent to treat adults with moderate-to-severe bullous pemphigoid, backed by a pivotal LIBERTY-BP-ADEPT trial showing over four times more patients on Dupixent achieved sustained remission versus placebo through Week 36.
• This decision adds a seventh Japanese indication for Dupixent and introduces the first targeted, non-immunosuppressant therapy for a rare, relapsing skin disease that currently has few treatment options.
• Next, we’ll examine how this new bullous pemphigoid indication for Dupixent in Japan could reshape Regeneron’s expanding immunology-driven investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Regeneron Pharmaceuticals Investment Narrative Recap

To own Regeneron, you need to believe its core franchises, especially EYLEA and Dupixent, can keep funding a broad, R&D heavy pipeline even as pricing and biosimilar pressures build. The new Dupixent approval in Japan for bullous pemphigoid reinforces the immunology story, but it does not directly change the key near term swing factor around defending EYLEA against competition or the broader risk of drug price pressure on its largest brands.

Among recent developments, the FDA’s decision to allow EYLEA HD dosing intervals up to 20 weeks in wet age related macular degeneration and diabetic macular edema is especially important. While Dupixent’s new indication highlights the breadth of Regeneron’s type 2 inflammation portfolio, EYLEA HD’s label expansion sits closer to the short term revenue debate and could matter more for how investors weigh the trade off between dependence on mature assets and the promise of future growth.

Yet against the appeal of expanded Dupixent uses, investors should still be aware that...

Read the full narrative on Regeneron Pharmaceuticals (it's free!)

Regeneron Pharmaceuticals’ narrative projects $18.7 billion revenue and $6.0 billion earnings by 2029.

Uncover how Regeneron Pharmaceuticals' forecasts yield a $873.78 fair value, a 15% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts already expected Regeneron to reach about US$17,800,000,000 in revenue and US$6,200,000,000 in earnings by 2028, so this fresh Dupixent win may either reinforce that bullish view or prompt a rethink on just how exposed those forecasts are to pricing pressure on EYLEA and Dupixent themselves.

Explore 9 other fair value estimates on Regeneron Pharmaceuticals - why the stock might be worth over 2x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Regeneron Pharmaceuticals research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Regeneron Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Regeneron Pharmaceuticals' overall financial health at a glance.

Seeking Other Investments?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• AI is about to change healthcare. These 37 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com